| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2014: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2012: ¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
|
|---|
| Outline of Final Research Achievements |
The prognosis of neuroblastoma patients is poor. Thus, to develop a novel treatment is necessary. Our previous studies show that poliovirus has strong anti-neuroblastoma effects both in vitro and in vivo, and anti-neuroblastoma immune response was induced in neuroblastoma cured mice. In accordance with these findings, we started phase 1 clinical trial for relapse and refractory neuroblastoma patients. We have treated two relapsed neuroblastoma patients so far.
|
